Rna Diagnostics announced the launch of an international prospective clinical trial to validate the RNA Disruption Assay™ (RDA™) as a tool for treatment management of primary breast cancer. BREVITY (Breast Cancer Response EValuation for Individualized TherapY) will include 500+ patients with invasive breast cancer, scheduled to receive neoadjuvant chemotherapy, in 40 centers across North America and Europe.
“BREVITY is a significant investment for Rna Diagnostics. It will be critical for commercial launch and clinician acceptance of RDA. The first set of kickoff meetings with our Clinical Investigators was held in March/April in the US and Europe. The objectives and design of BREVITY reflect feedback received from Key Opinion Leaders in breast cancer research from centers in Europe, Canada and the US. Accrual of patients will begin in the second half of 2017.”
For the full press release click here